These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 3700040)
21. Acivicin. An antitumor antibiotic. Poster DS; Bruno S; Penta J; Neil GL; McGovren JP Cancer Clin Trials; 1981; 4(3):327-30. PubMed ID: 7026076 [TBL] [Abstract][Full Text] [Related]
22. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. Polee MB; Verweij J; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A Eur J Cancer; 2002 Jul; 38(11):1495-500. PubMed ID: 12110496 [TBL] [Abstract][Full Text] [Related]
23. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125 [TBL] [Abstract][Full Text] [Related]
24. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Jayaram HN; Ardalan B; Deas M; Johnson RK Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092 [TBL] [Abstract][Full Text] [Related]
25. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study. Thigpen JT; Blessing JA; Homesley HD; Lewis GC Gynecol Oncol; 1986 Mar; 23(3):358-63. PubMed ID: 3754234 [TBL] [Abstract][Full Text] [Related]
26. Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma. Martino S; Decker DA; Hynes HE; Kresge CL Invest New Drugs; 1987 Dec; 5(4):373-4. PubMed ID: 3481362 [TBL] [Abstract][Full Text] [Related]
27. A phase II trial of peplomycin in squamous cell carcinoma of the lung. Sørensen PG; Rørth M; Hansen HH; Dombernowsky P; Høst H Eur J Cancer Clin Oncol; 1983 Jan; 19(1):25-7. PubMed ID: 6189718 [TBL] [Abstract][Full Text] [Related]
28. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD Cancer Chemother Pharmacol; 1990; 26 Suppl():S55-8. PubMed ID: 2112054 [TBL] [Abstract][Full Text] [Related]
29. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study. Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903 [TBL] [Abstract][Full Text] [Related]
30. Phase I study of acivicin and cisplatin in non-small-cell lung cancer. A National Cancer Institute of Canada study. Maroun JA; Stewart DJ; Verma S; Evans WK; Eisenhauer E Am J Clin Oncol; 1990 Oct; 13(5):401-4. PubMed ID: 2171318 [TBL] [Abstract][Full Text] [Related]
31. Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study. Stehman FB; Blom J; Blessing JA; Ehrlich CE; Mangan C Gynecol Oncol; 1983 Jun; 15(3):381-90. PubMed ID: 6862293 [TBL] [Abstract][Full Text] [Related]
32. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study. Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558 [No Abstract] [Full Text] [Related]
33. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221 [TBL] [Abstract][Full Text] [Related]
34. Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Bonomi P; Finkelstein D; Chang A Am J Clin Oncol; 1994 Jun; 17(3):215-7. PubMed ID: 8192104 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Rose PG; Blessing JA; Lele S; Abulafia O Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. McGuire WP; Blessing JA; Yordan E; Beecham J Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379 [TBL] [Abstract][Full Text] [Related]
38. Response of tumor and host to hyperalimentation and antiglutamine treatments. Chance WT; Cao LQ; Fischer JE JPEN J Parenter Enteral Nutr; 1990; 14(2):122-8. PubMed ID: 2112618 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials. McGovren JP; Pratt EA; Belt RJ; Taylor SA; Benjamin RS; Ardalan B; Ohnuma T Cancer Res; 1985 Sep; 45(9):4460-3. PubMed ID: 3896481 [TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Weiss GR; McGovren JP; Schade D; Kufe DW Cancer Res; 1982 Sep; 42(9):3892-5. PubMed ID: 7105049 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]